This story has been updated to clarify Luis Diaz's affiliation with liquid biopsy firm PGDx.

NEW YORK (GenomeWeb) – Liquid biopsy firm Cynvenio Biosystems announced earlier this month that it is now offering a blood-based monitoring service to track disease status or to surveil for early signs of recurrence in breast cancer patients.

This type of monitoring has been the focus of significant attention amongst liquid biopsy researchers. But to date, most clinical testing remains limited to less frequent analyses.